Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS

Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune... 1 Introduction</h5> The cannabinoid system consists of cannabinoid receptors and both exogenous and endogenous receptor ligands. Most cannabinoid actions are mediated through the classical CB1 and CB2 receptors, with a preferential but not exclusive distribution in the CNS and periphery, respectively [reviewed in [1–4] ]. The exogenous ligands include natural (plant derived) ligands and synthetic CB1/CB2 agonists and inverse agonist/antagonists [2,4] . The best characterized endocannabinoids include anandamide (AEA) and 2-arachydonoylglycerol (2-AG), both partial CB1/CB2 agonists [4,5] .</P>The CB1 receptors are located primarily in the CNS at neuronal terminals and regulate neurotransmitter release and psychoactivity. In contrast, the CB2 receptors are expressed primarily on immune cells in the periphery, and during neuroinflammation on activated microglia in the CNS [2,4] . Changes in cannabinoid receptor expression and in endocannabinoid levels have been reported in several pathological conditions, leading to proposed roles of CB1/CB2 receptors in various diseases [reviewed in [1] ]. The therapeutic potential of CB2 receptor signaling in a wide array of diseases has been reviewed recently [2] . Important considerations for developing highly selective CB2 receptor agonists include absence of psychoactive effects, sustained anti-inflammatory activity, tissue/cell protection, lack of cardiovascular adverse effects, and efficacy in several disease http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cellular Immunology Elsevier

Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS

Loading next page...
 
/lp/elsevier/selective-cb2-receptor-activation-ameliorates-eae-by-reducing-th17-Y2uMHW9YiD
Publisher
Elsevier
Copyright
Copyright © 2013 Elsevier Inc.
ISSN
0008-8749
eISSN
1090-2163
DOI
10.1016/j.cellimm.2013.11.002
Publisher site
See Article on Publisher Site

Abstract

1 Introduction</h5> The cannabinoid system consists of cannabinoid receptors and both exogenous and endogenous receptor ligands. Most cannabinoid actions are mediated through the classical CB1 and CB2 receptors, with a preferential but not exclusive distribution in the CNS and periphery, respectively [reviewed in [1–4] ]. The exogenous ligands include natural (plant derived) ligands and synthetic CB1/CB2 agonists and inverse agonist/antagonists [2,4] . The best characterized endocannabinoids include anandamide (AEA) and 2-arachydonoylglycerol (2-AG), both partial CB1/CB2 agonists [4,5] .</P>The CB1 receptors are located primarily in the CNS at neuronal terminals and regulate neurotransmitter release and psychoactivity. In contrast, the CB2 receptors are expressed primarily on immune cells in the periphery, and during neuroinflammation on activated microglia in the CNS [2,4] . Changes in cannabinoid receptor expression and in endocannabinoid levels have been reported in several pathological conditions, leading to proposed roles of CB1/CB2 receptors in various diseases [reviewed in [1] ]. The therapeutic potential of CB2 receptor signaling in a wide array of diseases has been reviewed recently [2] . Important considerations for developing highly selective CB2 receptor agonists include absence of psychoactive effects, sustained anti-inflammatory activity, tissue/cell protection, lack of cardiovascular adverse effects, and efficacy in several disease

Journal

Cellular ImmunologyElsevier

Published: Jan 1, 2014

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off